TITLE 25.HEALTH SERVICES

Part 1. TEXAS DEPARTMENT OF HEALTH

Chapter 31. NUTRITION SERVICES

25 TAC §31.1

The Texas Department of Health (department) adopts under federal mandate an amendment to §31.1 concerning the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC). Section 31.1(c) adopts by reference the WIC Policy and Procedure Manual.

The amendment to the WIC Policy and Procedure Manual covers United States Department of Agriculture (USDA) regulations which were incorporated into a policy that was approved by USDA. The department drafted an amendment to certification policy CS: 03.5, Texas WIC Income Guidelines, submitted the amendment for review by the Board of Health at its meeting on May 17, 2000, and subsequently received USDA final approval. The amendment will allow the department to announce and transmit to each local agency the changes in the federal poverty income guidelines issued by the United States Department of Health and Human Services by July 1, 2000, as required by USDA.

The amendment is adopted under federal mandate for the following reasons. Under federal and state enabling legislation (the Child Nutrition Act of 1966, 42 USC §1786; and the Texas Omnibus Hunger Act of 1985, 69th Legislature, Chapter 150, Title II), the WIC Program is 99% federally funded and governed by federal regulations. Funds are made available to the department by a federal grant. The federal statute (42 USC §1786), federal regulations (7 CFR Part 246), and the federal grant (Federal-State Special Supplemental Nutrition Program Agreement) authorize the USDA to make funds available to the department to administer the WIC Program in the State of Texas, provided that the department administers the program in accordance with the federal regulations.

The amendment is adopted under Health and Safety Code, §12.001(b) which provides the Texas Board of Health (board) with authority to adopt rules for the performance of every duty imposed by law upon the board, the department, and the commissioner of health; the Texas Omnibus Hunger Act of 1985, 69th Legislature, Chapter 150, Title II, Human Resources Code, Chapter 33; the Child Nutrition Act of 1966, 42 USC §1786; and 7 CFR Part 246.

§31.1.Special Supplemental Food Program for Women, Infants and Children (WIC).

(a)

Federal regulations.

(1)

The department adopts by reference the United States Department of Agriculture regulations on the Special Supplemental Food Program for Women, Infants, and Children (WIC). These regulations are contained in the Federal Register publication entitled "Special Supplemental Food Program for Women, Infants, and Children" dated February 13, 1985, as amended October 4, 1993, November 29, 1993, March 10, 1994, and March 11, 1994.

(2)

Copies of the regulations described in paragraph (1) of this subsection are filed in the department's Bureau of Nutrition Services-Women, Infants, and Children (WIC) Program, Texas Department of Health, 1100 West 49th Street, Austin, Texas 78756, and are available for public inspection during regular working hours.

(b)

WIC State Plan of Operations.

(1)

The department adopts by reference the publication titled "WIC State Plan of Operations," as amended effective October 1, 1998. This plan has been developed by the department's WIC Program and approved by the United States Department of Agriculture.

(2)

Copies of the state plan are filed in the department's Bureau of Nutrition Services-Women, Infants, and Children (WIC) Program, Texas Department of Health, 1100 West 49th Street, Austin, Texas 78756, and are available for public inspection during regular working hours.

(c)

WIC Policy and Procedure Manual

(1)

The department adopts by reference the publication titled "WIC Policy and Procedure Manual," which the department developed, as amended effective July 1, 2000. This policy and procedure manual has been developed by the department's WIC Program and approved by the United States Department of Agriculture.

(2)

Copies of the manual are filed in the department's Bureau of Nutrition Services- Women, Infants, and Children (WIC) Program, Texas Department of Health, 1100 West 49th Street, Austin, Texas 78756, and are available for public inspection during regular working hours.

This agency hereby certifies that the adoption has been reviewed by legal counsel and found to be a valid exercise of the agency's legal authority.

Filed with the Office of the Secretary of State on June 23, 2000.

TRD-200004411

Susan K. Steeg

General Counsel

Texas Department of Health

Effective date: July 1, 2000

For further information, please call: (512) 458-7236


Chapter 61. CHRONIC DISEASES

Subchapter D. OSTEOPOROSIS ADVISORY COMMITTEE

25 TAC §61.61

The Texas Department of Health (department) adopts an amendment to §61.61 concerning the Osteoporosis Advisory Committee (committee) without changes to the proposed text as published in the April 14, 2000, issue of the Texas Register (25 TexReg 3161), and therefore the section will not be republished. The committee provides advice to the Texas Board of Health (board) concerning the rules relating to educating the public on the health benefits of the early detection, prevention, and treatment of osteoporosis.

In 1993, the Texas Legislature passed Senate Bill 383 (now codified in the Government Code, Chapter 2110), which requires that each state agency adopt rules on advisory committees. The rules must state the purpose and tasks of the committee, describe the manner in which the committee will report to the agency, and establish a date on which the committee will be automatically abolished unless the governing body of the agency affirmatively votes to continue the committee's existence.

In 1996, the board established a rule relating to the Osteoporosis Advisory Committee. The rule states that the committee will automatically be abolished on September 1, 2000. The board has now reviewed and evaluated the committee and has determined that the committee should continue in existence until September 1, 2004.

This section amends provisions relating to the operation of the committee. Specifically, language is revised to reference the Health and Safety Code, §11.016 and the Government Code; to continue the committee until September 1, 2004; to change the composition; to clarify that members holdover until their replacement is appointed; to state that the presiding and assistant presiding officers shall be appointed by the chairman of the board for a term of two years; to allow a temporary vacancy in the office of assistant presiding officer to be filled by vote of the committee until appointment by the chairman of the board occurs; to clarify that the committee is prohibited from holding an executive session (closed meeting) for any reason; to clarify that the committee and its members may not participate in legislative activity in the name of the board, the department, or the committee except with certain approval; to require the committee's annual report in September rather than January; and to reference reimbursement for a committee member's expenses if authorized by the General Appropriations Act or budget execution process. Other minor language changes were made for clarification. These changes will clarify procedures for the committee and emphasize the advisory nature of the committee.

No comments were received on the proposal during the comment period.

The amendment is adopted under the Health and Safety Code, §90.003 which allows the appointment of an osteoporosis task force; Health and Safety Code, §11.016, which allows the board to establish advisory committees; the Government Code, Chapter 2110, which sets standards for the evaluation of advisory committees by the agencies for which they function; and the Health and Safety Code, §12.001, which provides the board with authority to adopt rules for the performance of every duty imposed by law upon the board, the department, and commissioner of health.

This agency hereby certifies that the adoption has been reviewed by legal counsel and found to be a valid exercise of the agency's legal authority.

Filed with the Office of the Secretary of State on June 26, 2000.

TRD-200004448

Susan K. Steeg

General Counsel

Texas Department of Health

Effective date: July 16, 2000

Proposal publication date: March 10, 2000

For further information, please call: (512) 458-7236


Chapter 159. TERTIARY MEDICAL CARE

25 TAC §159.1

The Texas Department of Health (department) adopts new §159.1 concerning reimbursement for tertiary medical services and stabilization services. Section 159.1 is adopted with changes to the proposed text as published in the March 10, 2000, issue of the Texas Register (25 TexReg 1956).

House Bill 1398, passed in 1999 by the Texas Legislature, added Chapter 46 to the Health and Safety Code, which establishes a method by which the department may allocate funds to certain facilities for unreimbursed tertiary medical services and unreimbursed stabilization services provided to persons who reside outside the service area of the county, public hospital, or hospital district that is responsible for indigent health care under the Health and Safety Code, Chapter 61, in the area in which the eligible facility is located. Chapter 46 established the tertiary care account in the state treasury, from which funds are appropriated to the department for the purposes of this chapter.

Health and Safety Code, Chapter 46, requires the Board of Health (board) to adopt rules governing the collection of information relating to unreimbursed tertiary medical services or stabilization services. The final rule specifies the information eligible facilities are required to provide to the department in order to receive funding under this chapter. The rule establishes a process for allocation of funds when the total costs certified are greater than the amount available in the tertiary care account and a process by which eligible facilities may apply for reimbursement under extraordinary emergencies.

The following written comments were received from the public:

Comment: Concerning proposed §159.1(b)(5), a comment was received that the definition of "tertiary medical services" should reflect the statutory definition.

Response: The department agrees and this change was made in renumbered §159.1(b)(7).

Comment: A comment was received that requested the addition of definitions for "cost of tertiary care services" and "cost of stabilization services."

Response: The department agrees and added these definitions as §159.1(b)(1) and (2), but changed the term "cost of tertiary care services" to "cost of tertiary medical services" to reflect terminology used elsewhere in the rule. Adding these definitions meant the subsequent definitions were renumbered.

Comment: Concerning proposed §159.1(d)(3), a comment was received that asked to eliminate the requirement that the chairman of the facility's board of directors sign the application for funds.

Response: The department disagrees that this requirement is a costly administrative burden to facilities because the signature is required only once a year and the board is ultimately responsible for the facility's financial operations. No change was made.

Comment: Concerning proposed §159.1(f), a comment was received that the rule should include statutory language concerning the percentage of available funds to be allocated for stabilization services.

Response: The department agrees and has added new paragraph (3) to §159.1(f).

The new section is adopted under the Health and Safety Code, Chapter 46, as added by Acts 1999, 76th Legislature, Chapter 1377 (House Bill 1398), Article 2, which provides the board with the authority to adopt rules concerning tertiary medical care; and §12.001 which provides the board with the authority to adopt rules for the performance of every duty imposed by law on the board, the department, and the commissioner of health.

§159.1.Reimbursement to Tertiary Care Facilities and Level IV Trauma Facilities.

(a)

Introduction. The Texas Department of Health (department) shall, on an annual basis, allocate available funds to eligible facilities to compensate the facilities for the costs of unreimbursed tertiary medical services and unreimbursed stabilization services.

(b)

Definitions. The following words and terms, when used in this chapter, shall have the following meanings, unless the context clearly indicates otherwise.

(1)

Cost of tertiary medical services - The cost of a tertiary medical service provided by a tertiary care facility is the average amount payable under Medicare reimbursement policies for that service.

(2)

Cost of stabilization services - The cost of a stabilization service provided by a tertiary care facility or level IV trauma facility is the average amount payable under Medicare reimbursement policies for that service.

(3)

Emergency reserve - Five percent of the total amount of funds in the Tertiary Care Account to be used only for reimbursement of unreimbursed tertiary medical services or unreimbursed stabilization services resulting from an extraordinary emergency.

(4)

Stabilization services - Services provided by a tertiary care facility or a designated level IV trauma center that are necessary to assure, within reasonable medical probability, that no material deterioration of a patient's medical condition is likely to result from or occur during the transfer of the patient to a tertiary care facility.

(5)

Tertiary Care Account - An account in the state treasury.

(6)

Tertiary care facility - A primary teaching hospital of a medical school or a designated level I, II or III trauma center.

(7)

Tertiary medical services - Includes, but is not limited to services provided by state-designated trauma center services, burn center treatment, neonatology level III unit services, pediatric surgery, trauma surgery, neurosurgery, cardiothoracic and vascular surgery, organ transplant, services provided for a life-threatening dermatologic illness, services provided to a person with a high-risk pregnancy or cancer, and radiation oncology.

(8)

Unreimbursed stabilization services - Stabilization services for which a tertiary care facility or a designated level IV trauma center has not received full payment from any public or private source.

(9)

Unreimbursed tertiary medical services - Tertiary medical services for which a tertiary care facility has not received full payment from any public or private source.

(c)

Eligibility for funds.

(1)

The department shall allocate available funds for unreimbursed tertiary medical services to tertiary care facilities who submit the required information on a timely basis.

(2)

The department shall allocate available funds for unreimbursed stabilization services to tertiary care facilities and designated level IV trauma centers who submit the required information on a timely basis.

(3)

A facility must have operated as a tertiary care facility or level IV trauma facility during the previous calendar year in order to claim costs of unreimbursed services.

(d)

Application for funds.

(1)

On an annual basis, the department, in writing, will inform each tertiary care facility and level IV trauma facility of the following:

(A)

that it may apply for funds to compensate it for the costs of unreimbursed tertiary medical services (tertiary care facilities only) and unreimbursed stabilization services (tertiary care facilities and level IV trauma facilities) provided to persons who reside outside the service area of the county, public hospital, or hospital district that is responsible for indigent health care under the Health and Safety Code, Chapter 61, in the area in which the tertiary care facility or level IV trauma facility is located;

(B)

the estimated, total amount of funding available at the end of the reporting period;

(C)

the number of facilities eligible to apply for funds;

(D)

the information required to be submitted to the department in order to apply for the funds;

(E)

the date by which the information must be submitted to the department; and

(F)

the date by which the department expects to certify amounts to the state comptroller of public accounts.

(2)

By the date established by the department, each tertiary care facility or level IV trauma facility must submit the following information on a form provided by the department:

(A)

name of the facility;

(B)

location including mailing address, city and county;

(C)

total costs of unreimbursed tertiary medical services (tertiary care facilities only) provided during the reporting period to persons who reside outside the service area of the county, public hospital, or hospital district that is responsible for indigent health care under the Health and Safety Code, Chapter 61, in the area in which the tertiary care facility is located; and

(D)

total costs of unreimbursed stabilization services (tertiary care facilities and level IV trauma facilities) provided during the reporting period to persons who reside outside the service area of the county, public hospital, or hospital district that is responsible for indigent health care under the Health and Safety Code, Chapter 61, in the area in which the tertiary care facility or level IV trauma facility is located.

(3)

The form must be signed by the chief operating officer and the chairman of the facility's board of directors.

(4)

The form must be notarized.

(5)

A form postmarked after the due date will not be considered for allocation of funds.

(6)

If a facility receives partial reimbursement from another source for its tertiary medical services or stabilization services provided to persons who reside outside the service area of the county, public hospital, or hospital district that is responsible for indigent health care under the Health and Safety Code, Chapter 61, in the area in which the tertiary care facility or level IV trauma facility is located, the facility may request compensation for the portion of the costs not covered by the partial reimbursement.

(7)

By signing the application form, a facility that is reimbursed in full by a private or public source for tertiary medical services or stabilization services after the services have been reported to the department, agrees to promptly reimburse the State of Texas for such funds paid to the facility under this section.

(e)

Reporting period. A facility's annual application for funds shall apply to costs incurred during the preceding state fiscal year, beginning with State Fiscal Year 2000 (September 1, 1999 to August 31, 2000).

(f)

Allocation of funds.

(1)

If the total cost of unreimbursed tertiary medical services certified for all eligible facilities exceeds the amount available in the Tertiary Care Account, the department shall allocate funds based on percentages computed by dividing the costs of each facility's unreimbursed tertiary medical services by the total cost of all facilities' unreimbursed tertiary medical services.

(2)

If the total cost of unreimbursed stabilization services certified for all eligible facilities exceeds the amount available in the Tertiary Care Account, the department shall allocate funds based on percentages computed by dividing the costs of each facility's unreimbursed stabilization services by the total cost of all facilities' unreimbursed stabilization services.

(3)

The department may allocate not more than four percent of available funds to eligible facilities for the cost of unreimbursed stabilization services.

(g)

Certification to comptroller. Once the department has determined the amount of reimbursement allotted for each eligible facility, the department will certify those amounts to the state comptroller of public accounts for processing of payments.

(h)

Emergency reserve.

(1)

The department may allocate funds to tertiary care facilities or level IV trauma centers to compensate the facilities for the costs of unreimbursed tertiary medical services or unreimbursed stabilization services resulting from an extraordinary emergency.

(2)

An extraordinary emergency shall be certified by the department:

(A)

if the governor issues an executive order or a proclamation under Government Code, Chapter 418, pertaining to emergency management;

(B)

if a disaster is declared by the president of the United States under the Robert T. Stafford Disaster Relief and Emergency Assistance Act (42 U.S.C. §5121 et seq.); or

(C)

for another similiar disaster the department finds has resulted in an extraordinary cost to a tertiary care facility or level IV trauma facility.

(3)

A facility which incurs costs as a result of an extraordinary emergency may apply to the department at any time; however, reimbursement may be provided only for costs incurred during the emergency.

(4)

The facility must submit, in writing, the following information:

(A)

name of the facility;

(B)

location including mailing address, city and county;

(C)

total costs of unreimbursed tertiary medical services (tertiary care facilities only) resulting from an extraordinary emergency;

(D)

total costs of unreimbursed stabilization services (tertiary care facilities and level IV trauma facilities) resulting from an extraordinary emergency; and

(E)

a description of the extraordinary emergency.

(5)

The written statement must be signed by the chief operating officer and the chairman of the facility's board of directors.

(6)

The department will review requests for emergency funds and certify costs to the state comptroller of public accounts until the emergency reserve is exhausted.

(i)

Audits. The department may conduct random, on-site audits of documentation used by the facilities to calculate their reported costs for unreimbursed services.

This agency hereby certifies that the adoption has been reviewed by legal counsel and found to be a valid exercise of the agency's legal authority.

Filed with the Office of the Secretary of State on June 26, 2000.

TRD-200004438

Susan K. Steeg

General Counsel

Texas Department of Health

Effective date: July 16, 2000

Proposal publication date: March 10, 2000

For further information, please call: (512) 458-7236


Chapter 229. FOOD AND DRUG

Subchapter Y. REGULATIONS TO SET STANDARDS FOR THE FORMULATION, SALE AND DISTRIBUTION OF DIETARY SUPPLEMENTS CONTAINING EPHEDRINE FROM NATURAL EPHIDRA ALKALOIDS AND TO RESTRICT THE SALE AND DISTRIBUTION OF CERTAIN DRUG PRODUCTS CONTAINING EPHEDRINE

25 TAC §229.462

The Texas Department of Health (department) adopts an amendment to §229.462 concerning product labels for dietary supplements containing ephedrine without changes to the proposed text as published in the February 4, 2000, issue of the Texas Register (25 TexReg 673), and therefore the section will not be republished.

Section 229.462(f) is amended to further protect the public health by providing the toll-free number the department has chosen to allow consumers to report adverse events associated with consumption of ephedrine-containing dietary supplements. The U.S. Food and Drug Administration (FDA) MedWatch reporting program is a nationally accessible toll-free number to be used for the reporting of adverse events. This number is 1-800-332-1088 and will be required on all labels of ephedrine containing dietary supplements after September 1, 2001, entering commerce in the state. The purpose of this section is to allow consumers to report adverse events associated with the use of ephedrine-containing dietary supplements. Adverse events monitoring systems, such as the FDA MedWatch program, are designed to identify unanticipated or unintended safety problems with use of marketed products. Patterns of adverse events help the FDA identify the need for further investigation to determine whether public health actions are needed. The information will be collected by the FDA and will be available for review to all interested parties.

Senate Bill 656, 76th Legislature, 1999, amended Health and Safety Code §431.022(c) to require the department to amend the labeling of dietary supplements by the addition of a warning statement on the product label or an auxiliary label such as a sticker permanently affixed to the product container prohibiting the sale of dietary supplements containing ephedrine to persons 17 years of age or younger after January 1, 2001. Section 229.462(h) will also aid in preventing minors from access to a product that is not indicated for safe use in that age population.

The following comments were received concerning the proposed sections. Following each comment is the department's response and any resulting change(s).

Comment: Concerning §229.462(f), several commenters questioned the effectiveness of the FDA's MedWatch number, citing the United States General Accounting Office report issued in July 1999 entitled Uncertainties in Analyses Underlying FDA's Proposed Rule on Ephedrine Alkaloids as evidence of the inability of the Food and Drug Administration to process and analyze the adverse events submitted to the MedWatch program. It is believed that the existing flaws in the MedWatch system will be exacerbated by the increase in unfiltered direct-from-consumer contacts.

Response: The department disagrees. The MedWatch program provides a voluntary passive reporting system whereby consumers may report adverse events associated with product consumption. The department believes that the FDA has made and will continue to make concerted efforts to improve the program in response to criticism of any real or perceived weaknesses. The September 1, 2001, rule implementation date provides a reasonable time frame to gauge progress in that endeavor. No change was made as a result of these comments.

Comment: Concerning §229.462(f), several commenters stated that the FDA's MedWatch number is intended for health professionals only.

Response: The department disagrees. Per the FDA, access to the MedWatch system for adverse event reporting is not limited to health care professionals. No change was made as a result of these comments.

Comment: Concerning §229.462(f), several commenters stated that consumers are already permitted to contact MedWatch on their own and requiring the MedWatch number to be published on the label is no more than free publicity for the MedWatch program. The department should focus on spending money on education campaigns directing consumers to call MedWatch.

Response: The department disagrees. The purpose of requiring the MedWatch number on the product label is to provide the consumer immediate access in reporting adverse events associated with consumption of dietary supplements containing ephedrine. No change was made as a result of these comments.

Comment: Concerning §229.462(f), several commenters stated that no other dietary supplement, over-the-counter drug, or prescription drug is required to publish this number. Ephedrine products will be unfairly targeted and perceived to be dangerous.

Response: The department disagrees. Since there are no established and recognized requirements relative to safe dosing intake or ingredient level, there is a strong likelihood of a lack of any uniformity among different products. Products suspected of causing adverse events can be more expeditiously identified if the consumer has access to a single point for reporting adverse events associated with product consumption. No change was made as a result of these comments.

Comment: Concerning §229.462(f), several commenters believe that the FDA will be overwhelmed by the sheer volume of reports.

Response: The department disagrees. Per the FDA, the MedWatch program is intended to handle reports from the entire nation. No change was made as a result of these comments.

Comment: Concerning §229.462(f), several commenters believe that MedWatch will not further the department's objectives as stated in the proposed rules, since the department itself stated that MedWatch needs to be fixed.

Response: The department disagrees. The department recognizes that there has been criticism that the MedWatch program lacks resources to be as effective as it can be. However, that does not mean that the department believes MedWatch to be ineffective. Early identification of a product that may be causing adverse events is the first step in addressing the question of whether that product presents a health threat to the consuming public. Reports received from consumers with ready access to a telephone number to make reports provide that early identification. No change was made as a result of these comments.

Comment: Concerning §229.462(f), several commenters indicated that MedWatch was intended to collect reports of serious events only.

Response: The department disagrees. Consumers will be reporting adverse events, and the FDA will make the determination of whether the event requires any further investigative action. No change was made as a result of these comments.

Comment: Concerning §229.462(f), one commenter stated that consumers do not understand the purpose of MedWatch.

Response: The department does not agree that it is necessary for consumers to understand the purpose of MedWatch in order for them to report adverse events. The term "adverse event" is self-explanatory, and persons experiencing such events can be expected to report them. No change was made as a result of this comment.

Comment: Concerning §229.462(f), several commenters question the September 1, 2001, effective date.

Response: The department recognizes that for industry to make a change to the manner in which it prepares a product for introduction into commerce cannot be reasonably accomplished without permitting industry time to adjust to that requirement. The department believes that a delayed implementation date of more than a year in the future is reasonable to make such an adjustment. An additional benefit for a delayed implementation date is the opportunity for the FDA to make further improvements to its MedWatch system. No change was made as a result of these comments.

Comment: Concerning §229.462(f), several commenters stated that consumers will expect the MedWatch number to be customer service oriented. They feel that consumers wishing to have questions answered will not have the opportunity to do so. They further suggested that the department should use an alternative program that has the goal of being a consumer-friendly information program.

Response: The department disagrees. The requirement for a product label to contain a telephone number where consumers may report adverse events associated with product consumption does not preclude a different number being placed on the product label for the use of consumers for other purposes. No change was made as a result of these comments.

Comment: Concerning §229.462(f), commenters believe that companies will not receive reports of adverse events from its customers since FDA will most likely not forward those calls to the firm.

Response: The department disagrees. Industry is not prevented from advising consumers to also contact the company concerning adverse events. In addition, all reports made to the FDA are available under the Freedom of Information Act. No change was made as a result of these comments.

Comment: Concerning §229.462(f), several commenters believe that FDA will view all calls as adverse events, even if they are not.

Response: The department disagrees. The MedWatch number is a reporting system. Consumers are expected to report to the MedWatch number if they feel they have experienced an adverse event. Follow-up investigation is the responsibility of the FDA. No change was made as a result of these comments.

Comment: Concerning §229.462(f), several commenters stated that the department cannot justify the rule requiring the MedWatch number based on the small number of adverse events it has received concerning the consumption of ephedrine. Initial numbers of adverse events can be attributed to one company only, and there are few current adverse events.

Response: The department disagrees. Ample justification has been provided to the department for the need for a toll free number for consumers to report adverse events. Neither the department, nor any other agency, currently has access to all complaints reported concerning dietary supplements. Collection of this information by an agency subject to freedom of information review will allow all interested parties to review the data. Since 1995, over 700 adverse events associated with the consumption of ephedrine have been reported to the department since the passage of the Dietary Supplement Health and Education Act. No change was made as a result of these comments.

Comment: Concerning §229.462(f), one commenter believes that reports from consumers to MedWatch are "worthless".

Response: The department disagrees. Adverse event reports from consumers will be examined by the FDA and further investigation will be made if necessary. No change was made as a result of this comment.

Comment: Concerning §229.462(f), several commenters stated that the MedWatch system does not effectively track problems associated with dietary supplements.

Response: The department disagrees. The MedWatch system is a passive reporting system and fulfills its stated purpose. No change was made as a result of these comments.

Comment: Concerning §229.462(f), several commenters recommended that the department use the existing Central Texas Poison Control Center as the contact.

Response: The department disagrees. There are six regional centers for poison control that are designated as the regional poison control centers for the state. The regional poison control centers are intended to provide emergency information regarding the treatment of overdose and accidental or intentional exposures that result in serious or life-threatening situations. A consumer experiencing such an event may still contact a regional poison control center in an emergency. No change was made as a result of these comments.

Comment: Concerning §229.462(f), one commenter expressed concern that the funding and administration of the toll-free number is not under the control of Texas.

Response: The department disagrees. It is not necessary for the funding and administration/ operation of a toll-free number for consumers to report adverse events associated with consumption of dietary supplements containing ephedrine to be under the control of Texas, if Texas is confident that an existing reporting system can provide the level of assurance expected by the state. The department feels that the MedWatch system provides that assurance. No change was made as a result of this comment.

Comment: Concerning §229.462(f), one commenter stated that the warning statement already advises consumers to call a physician or licensed health care professional in the event of an adverse event. The physician can then evaluate the adverse event and call MedWatch, if necessary, so publishing the number on the bottle is redundant and unnecessary.

Response: The department disagrees. The MedWatch number allows the consumer the flexibility to self-report adverse events. No change was made as a result of this comment.

Comment: Concerning §229.462(f), several commenters recommended that the proposed rule be withdrawn and a working group from industry, consumer, trade associations, and all other stakeholders convene to develop an alternative consumer reporting system.

Response: The department disagrees. There is no compelling reason to develop an alternative reporting system to one that already exists. Moreover, industry at its request, was given an opportunity to present reporting system alternatives that could be discussed in a working group environment, and the department was advised that industry could not reach a consensus opinion on any alternatives that could be discussed. No change was made as a result of these comments.

Comment: Concerning §229.462(h), many commenters indicated that the statement prohibiting sales to those under 18 years of age is redundant since it is already addressed in the warning statement.

Response: The department disagrees. Prohibiting the sale of ephedrine-containing dietary supplements to persons 17 years of age and younger is a legislated restriction and violations may result in criminal penalties. Indicating that a product is not intended for use by persons under 18 is a consumer health warning precaution. No change was made as a result of these comments.

Comment: Concerning §229.462(h), one commenter felt that the language "sale to persons 17 years of age or younger is prohibited" is too lengthy.

Response: The department disagrees and notes that the rule does not dictate the exact wording of the statement, only that one be provided. No change was made as a result of this comment.

Comment: Concerning the rules in general, one commenter submitted signed petitions with the concern that the regulations will restrict access to dietary supplement products and information.

Response: The department disagrees. No restrictions have been placed on the dissemination of information or product literature. Ephedrine-containing dietary supplements have been required to comply with recent labeling requirements since November 1999. The proposed regulations concern amendments to existing regulations and do not place any additional burden on manufacturers other than changing the label. No change was made as a result of this comment.

Comment: Concerning the rules in general, one commenter expressed concern that the additional regulations will increase the cost of the products.

Response: The department disagrees. The effective date of September 1, 2001, will allow sufficient time for manufacturers to deplete existing labels, thus creating no additional costs associated with the new requirements. No change was made as a result of this comment.

The commenters were Congressman Dan Burton, Representative Rick Green, Representative Harvey Hilderbran, Representative Carl Isett, Senator Frank Madla, Citizens for Health, Consumer Healthcare Products Association, General Nutrition Centers, Arter and Hadden, LLP for Metabolife Intl., Bankowsky, Betz, & Levine for Omnitrition, Hyman, Phelps, & McNamara, P.C. for The Ephedra Committee of the American Herbal Products Association, Sidley & Austin for NNFA, and Ullman, Shapiro, & Ullman, LLP. In addition, numerous individuals commented. All commenters were not against the rules in their entirety; however, they expressed concerns, asked questions, and suggested recommendations for change as discussed in the summary of comments.

The amendment is adopted under the Texas Health and Safety Code, §431.241, which provides the department with the authority to adopt rules for the efficient enforcement of Chapter 431, the Texas Food, Drug, and Cosmetic Act; and §12.001, which provides the Texas Board of Health with the authority to adopt rules for the performance of every duty imposed by law on the Texas Board of Health, the Texas Department of Health, and the commissioner of health.

This agency hereby certifies that the adoption has been reviewed by legal counsel and found to be a valid exercise of the agency's legal authority.

Filed with the Office of the Secretary of State on June 26, 2000.

TRD-200004437

Susan K. Steeg

General Counsel

Texas Department of Health

Effective date: July 16, 2000

Proposal publication date: February 4, 2000

For further information, please call: (512) 458-7236